Parabilis Medicines

Update in progress

PBLS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company using its Helicon platform to develop stabilized helical peptide therapeutics that target traditionally undruggable proteins. Its pipeline includes intracellular protein–protein interaction inhibitors, targeted degraders, and targeted radiopharmaceuticals. Lead program FOG-001 blocks TCF/beta-catenin to treat cancer. The company leverages AI and data science in discovery and trial design. Founded 2015, Cambridge, MA.

Company score

Sentiment: 0.42; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.28; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEODr. Mathai Mammen M.D., Ph.D.
Founded2015
Employees145
Websiteparabilismed.com